Johnson & Johnson (NYSE: JNJ) announced today that 43 presentations showcasing the Company's rheumatology pipeline and portfolio will be featured at the American College of Rheumatology (ACR) 2024 ...

Dr Judy Chou, CEO, President and Board Member of AltruBio, Inc, explains how agonist antibodies show potential as a novel therapeutic approach in immunological diseases.

The brain, traditionally considered an immune-privileged organ due to the blood-brain barrier (BBB), has its own sophisticated immune defense system.